DRTS catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
December 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Dec 2026Sponsor estimate | NCT05047094Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCCAlpha Tau Medical LTD. · Head and Neck Squamous Cell Carcinoma | DRTSLead | No phase registered | Recruiting | Locked | Locked | Locked |
| Dec 2026Sponsor estimate | NCT06615635Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised PatientsAlpha Tau Medical LTD. · Squamous Cell Carcinoma | DRTSLead | No phase registered | Recruiting | Locked | Locked | Locked |
- Primary completion Dec 2026Sponsor estimateNo phase registeredNCT05047094Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCCAlpha Tau Medical LTD. · Head and Neck Squamous Cell CarcinomaRecruitingDRTSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimateNo phase registeredNCT06615635Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised PatientsAlpha Tau Medical LTD. · Squamous Cell CarcinomaRecruitingDRTSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
- Primary completion Jan 2027Sponsor estimateNo phase registeredNCT04068155Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous TumorsAlpha Tau Medical LTD. · Skin CancerRecruitingDRTSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimateNo phase registeredNCT06026943Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic CancerAlpha Tau Medical LTD. · Pancreatic CancerRecruitingDRTSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimateNo phase registeredNCT06755359Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic CancerAlpha Tau Medical LTD. · Pancreatic CancerRecruitingDRTSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 1, 2027Sponsor estimateNo phase registeredNCT04534127Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue NeoplasiaAlpha Tau Medical LTD. · Skin CancerRecruitingDRTSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 6 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.